Biomarkers reveal clue in treating aggressive prostate cancer, phase II study finds

Pentagon temporarily rescinds guidance on testosterone testing for U.S. military

The Pentagon has temporarily rescinded a recently published guidance that would require all military personnel aged 30 and over to receive testosterone level testing to check for deficiencies.

September 11, 2026

Vol.52 No.33

By Claire Marie Porter

In Brief

Andrew Hsieh named Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research at Fred Hutch

Andrew Hsieh, who serves as the associate director of Fred Hutch’s Human Biology Division, has been named the inaugural holder of the Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research.

September 11, 2026

Vol.52 No.33

Clinical Roundup

Zipalertinib + chemo meets primary endpoint in phase III REZILIENT3 trial in first-line EGFR exon 20 insertion mutation NSCLC

The REZILIENT3 trial, a global phase III clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone in the first-line treatment of adult patients with previously untreated, locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations, met its primary endpoint of progression-free survival at a planned interim analysis.

September 11, 2026

Vol.52 No.33

Clinical Roundup

Penn Medicine launches first human clinical trial to test precision form of FLASH proton therapy

A new form of proton therapy designed to deliver cancer-killing radiation therapy in less than a second, through fewer total sessions, with potentially less risk of damaging side effects, is now being tested in a phase I clinical trial at the Abramson Cancer Center of the University of Pennsylvania.

September 11, 2026

Vol.52 No.33

Clinical Roundup

Traditional prostate cancer risk factors do not predict hormone therapy benefit, UCLA-led study finds

Traditional pathological features used to classify aggressive prostate cancer—such as high-grade disease, cancer extending outside the prostate and cancer involving the seminal vesicles—after surgery do not predict who will benefit more from adding hormone therapy to postoperative radiation, according to a study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

August 14, 2026

Vol.52 No.32

Clinical Roundup

Half of prostate cancer focal therapy use falls outside current guideline-supported patient groups, study finds

As focal therapy gains popularity as a less invasive treatment option for some men with prostate cancer, a national study led by researchers at the University of Pittsburgh found that some men may be receiving treatment that is either unnecessary or not aggressive enough for their cancer.

August 14, 2026

Vol.52 No.32

Biomarkers reveal clue in treating aggressive prostate cancer, phase II study finds

YOU MAY BE INTERESTED IN

Pentagon temporarily rescinds guidance on testosterone testing for U.S. military

Andrew Hsieh named Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research at Fred Hutch

Zipalertinib + chemo meets primary endpoint in phase III REZILIENT3 trial in first-line EGFR exon 20 insertion mutation NSCLC

Penn Medicine launches first human clinical trial to test precision form of FLASH proton therapy

Traditional prostate cancer risk factors do not predict hormone therapy benefit, UCLA-led study finds

Half of prostate cancer focal therapy use falls outside current guideline-supported patient groups, study finds

Renew today!

Subscriber content

Never miss an issue!

Login